Baidu
map

CDS 2015 MedSci专访陈莉明教授:《中国血糖监测临床应用指南 2015》新版发布!

2015-12-13 MedSci MedSci原创

  2015年12月9日—12日,由中华医学会、中华医学会糖尿病学分会(CDS)主办,江苏省医学会承办的“中华医学会糖尿病学分会第十九次全国学术会议(CDS 2015)”在苏州国际博览中心举行。 本次会议是2015年国内外糖尿病学术领域的收官之作,是融合本年度美国糖尿病学会(ADA)、欧洲糖尿病研究协会(EASD)、国际糖尿病联盟(IDF)等年度会议精华内容,以及展现中国糖尿病学界基

2015年12月9日—12日,由中华医学会、中华医学会糖尿病学分会(CDS)主办,江苏省医学会承办的“中华医学会糖尿病学分会第十九次全国学术会议(CDS 2015)”在苏州国际博览中心举行。

本次会议是2015年国内外糖尿病学术领域的收官之作,是融合本年度美国糖尿病学会(ADA)、欧洲糖尿病研究协会(EASD)、国际糖尿病联盟(IDF)等年度会议精华内容,以及展现中国糖尿病学界基础科研最新成果和临床实践最新进展的学术盛宴。CDS 2015将围绕“创新、规范、普及”的主题,突出基础与临床结合、广度与深度并重、交流与培训并举、学术与公益兼顾等特点,学术氛围浓郁,形式丰富多样,内容精彩纷呈。

此次大会上对2015版《中国血糖监测临床应用指南》进行发布会。新版指南对现有的一下几类血糖监测方法进行了详细阐述:

毛细血管血糖监测:新版指南新增了医院内血糖监测推荐,其中以POCT为主,同时梳理了影响毛细血管血糖监测的诸多因素——血糖仪的准确性、毛细血管血糖与静脉血糖差异、干扰性因素和操作者技术。

糖化血红蛋白(HbA1c):HbA1c在临床上不仅是评估长期血糖控制状况的金标准,也是临床决定是否调整治疗的重要依据,但在我国暂不推荐用于糖尿病诊断,因为HbA1c具有种族差异,中国人群HbA1c诊断糖尿病切点可能有别于国外标准,并且我国HbA1c监测的普遍化、标准化程度偏低。

糖化白蛋白(GA):GA反应的是短期糖代谢状况的指标,在近期血糖水平的评估,诊断糖尿病患者的降糖疗效评估方面较HbA1c更有优势,在短期血糖变化较大时,GA的监测价价值更优于HbA1c。

动态血糖监测(CGM):CGM可提供连续、全面、可靠的全天血糖信息,了解血糖波动的趋势,发现隐匿性高血糖和低血糖。因此CGM成为创痛血糖监测方法的一种有效补充。

梅斯医学(MedSci)有幸采访了指南执笔专家陈莉明教授。

MedSci:陈教授,您好!请您简单跟我们分享一下《中国血糖监测临床应用指南 2015》指南的发布对于糖尿病患者诊治的重要意义?

陈莉明教授:不言而喻,此次指南的发布对于糖尿病具有重大的诊治意义,我国人口众多,各地经济发展水平不一,糖尿病诊治水平差别巨大,血糖监测使用现状也参差不齐。尤其在基层医院,出现了不管患者血糖水平和用药方案,一律采取连续血糖监测而血糖控制依旧无法改善现象。所以,为了推动我国糖尿病防治的标准化进程,提高我国整体糖尿病防治水平。

MedSci:很多临床专家在血糖监测过程中都会参考国外文献指南,此次指南的发布,是否参考了国外指南文献的研究数据?

陈莉明教授:此次指南的制定,大部分是参考国内的研究数据,在指南后面我们都附有参考来源,我们希望在未来,我们应该针对我国的循证医学证据和我国糖尿病防治临床实践修订指南,做更多的关于中国患者的研究,对指南不断的更新,加强指导性和实用性,从而调高我国整体糖尿病防治水平。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1835606, encodeId=c48e18356060a, content=<a href='/topic/show?id=cfdc22e893f' target=_blank style='color:#2F92EE;'>#临床应用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22789, encryptionId=cfdc22e893f, topicName=临床应用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Mon Jul 18 15:33:00 CST 2016, time=2016-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703203, encodeId=dffd1e032037e, content=<a href='/topic/show?id=dba720e31b7' target=_blank style='color:#2F92EE;'>#专访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20731, encryptionId=dba720e31b7, topicName=专访)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=070a30497323, createdName=flyingeagle87, createdTime=Mon Sep 05 15:33:00 CST 2016, time=2016-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48465, encodeId=3a1f48465eb, content=好文章,值得看。, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 17:17:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377590, encodeId=1d1f13e7590ce, content=<a href='/topic/show?id=5dfe4420fc' target=_blank style='color:#2F92EE;'>#CDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4420, encryptionId=5dfe4420fc, topicName=CDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec25412, createdName=yangpeizhi, createdTime=Tue Dec 15 02:33:00 CST 2015, time=2015-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540173, encodeId=891915401e39b, content=<a href='/topic/show?id=da548984604' target=_blank style='color:#2F92EE;'>#血糖监测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89846, encryptionId=da548984604, topicName=血糖监测)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50fd13191418, createdName=jktdtl, createdTime=Tue Dec 15 02:33:00 CST 2015, time=2015-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606768, encodeId=12321606e6869, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Dec 15 02:33:00 CST 2015, time=2015-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=46065, encodeId=8c9946065b4, content=指南熟记心中, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2d331664955, createdName=老段, createdTime=Mon Dec 14 07:32:00 CST 2015, time=2015-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=45774, encodeId=b1df45e740e, content=…………, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=554a1670659, createdName=yuwenpsy, createdTime=Sun Dec 13 22:26:00 CST 2015, time=2015-12-13, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1835606, encodeId=c48e18356060a, content=<a href='/topic/show?id=cfdc22e893f' target=_blank style='color:#2F92EE;'>#临床应用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22789, encryptionId=cfdc22e893f, topicName=临床应用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Mon Jul 18 15:33:00 CST 2016, time=2016-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703203, encodeId=dffd1e032037e, content=<a href='/topic/show?id=dba720e31b7' target=_blank style='color:#2F92EE;'>#专访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20731, encryptionId=dba720e31b7, topicName=专访)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=070a30497323, createdName=flyingeagle87, createdTime=Mon Sep 05 15:33:00 CST 2016, time=2016-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48465, encodeId=3a1f48465eb, content=好文章,值得看。, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 17:17:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377590, encodeId=1d1f13e7590ce, content=<a href='/topic/show?id=5dfe4420fc' target=_blank style='color:#2F92EE;'>#CDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4420, encryptionId=5dfe4420fc, topicName=CDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec25412, createdName=yangpeizhi, createdTime=Tue Dec 15 02:33:00 CST 2015, time=2015-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540173, encodeId=891915401e39b, content=<a href='/topic/show?id=da548984604' target=_blank style='color:#2F92EE;'>#血糖监测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89846, encryptionId=da548984604, topicName=血糖监测)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50fd13191418, createdName=jktdtl, createdTime=Tue Dec 15 02:33:00 CST 2015, time=2015-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606768, encodeId=12321606e6869, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Dec 15 02:33:00 CST 2015, time=2015-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=46065, encodeId=8c9946065b4, content=指南熟记心中, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2d331664955, createdName=老段, createdTime=Mon Dec 14 07:32:00 CST 2015, time=2015-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=45774, encodeId=b1df45e740e, content=…………, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=554a1670659, createdName=yuwenpsy, createdTime=Sun Dec 13 22:26:00 CST 2015, time=2015-12-13, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1835606, encodeId=c48e18356060a, content=<a href='/topic/show?id=cfdc22e893f' target=_blank style='color:#2F92EE;'>#临床应用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22789, encryptionId=cfdc22e893f, topicName=临床应用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Mon Jul 18 15:33:00 CST 2016, time=2016-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703203, encodeId=dffd1e032037e, content=<a href='/topic/show?id=dba720e31b7' target=_blank style='color:#2F92EE;'>#专访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20731, encryptionId=dba720e31b7, topicName=专访)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=070a30497323, createdName=flyingeagle87, createdTime=Mon Sep 05 15:33:00 CST 2016, time=2016-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48465, encodeId=3a1f48465eb, content=好文章,值得看。, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 17:17:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377590, encodeId=1d1f13e7590ce, content=<a href='/topic/show?id=5dfe4420fc' target=_blank style='color:#2F92EE;'>#CDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4420, encryptionId=5dfe4420fc, topicName=CDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec25412, createdName=yangpeizhi, createdTime=Tue Dec 15 02:33:00 CST 2015, time=2015-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540173, encodeId=891915401e39b, content=<a href='/topic/show?id=da548984604' target=_blank style='color:#2F92EE;'>#血糖监测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89846, encryptionId=da548984604, topicName=血糖监测)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50fd13191418, createdName=jktdtl, createdTime=Tue Dec 15 02:33:00 CST 2015, time=2015-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606768, encodeId=12321606e6869, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Dec 15 02:33:00 CST 2015, time=2015-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=46065, encodeId=8c9946065b4, content=指南熟记心中, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2d331664955, createdName=老段, createdTime=Mon Dec 14 07:32:00 CST 2015, time=2015-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=45774, encodeId=b1df45e740e, content=…………, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=554a1670659, createdName=yuwenpsy, createdTime=Sun Dec 13 22:26:00 CST 2015, time=2015-12-13, status=1, ipAttribution=)]
    2015-12-26 hixiaoluo

    好文章,值得看。

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1835606, encodeId=c48e18356060a, content=<a href='/topic/show?id=cfdc22e893f' target=_blank style='color:#2F92EE;'>#临床应用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22789, encryptionId=cfdc22e893f, topicName=临床应用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Mon Jul 18 15:33:00 CST 2016, time=2016-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703203, encodeId=dffd1e032037e, content=<a href='/topic/show?id=dba720e31b7' target=_blank style='color:#2F92EE;'>#专访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20731, encryptionId=dba720e31b7, topicName=专访)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=070a30497323, createdName=flyingeagle87, createdTime=Mon Sep 05 15:33:00 CST 2016, time=2016-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48465, encodeId=3a1f48465eb, content=好文章,值得看。, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 17:17:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377590, encodeId=1d1f13e7590ce, content=<a href='/topic/show?id=5dfe4420fc' target=_blank style='color:#2F92EE;'>#CDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4420, encryptionId=5dfe4420fc, topicName=CDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec25412, createdName=yangpeizhi, createdTime=Tue Dec 15 02:33:00 CST 2015, time=2015-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540173, encodeId=891915401e39b, content=<a href='/topic/show?id=da548984604' target=_blank style='color:#2F92EE;'>#血糖监测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89846, encryptionId=da548984604, topicName=血糖监测)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50fd13191418, createdName=jktdtl, createdTime=Tue Dec 15 02:33:00 CST 2015, time=2015-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606768, encodeId=12321606e6869, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Dec 15 02:33:00 CST 2015, time=2015-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=46065, encodeId=8c9946065b4, content=指南熟记心中, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2d331664955, createdName=老段, createdTime=Mon Dec 14 07:32:00 CST 2015, time=2015-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=45774, encodeId=b1df45e740e, content=…………, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=554a1670659, createdName=yuwenpsy, createdTime=Sun Dec 13 22:26:00 CST 2015, time=2015-12-13, status=1, ipAttribution=)]
    2015-12-15 yangpeizhi
  5. [GetPortalCommentsPageByObjectIdResponse(id=1835606, encodeId=c48e18356060a, content=<a href='/topic/show?id=cfdc22e893f' target=_blank style='color:#2F92EE;'>#临床应用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22789, encryptionId=cfdc22e893f, topicName=临床应用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Mon Jul 18 15:33:00 CST 2016, time=2016-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703203, encodeId=dffd1e032037e, content=<a href='/topic/show?id=dba720e31b7' target=_blank style='color:#2F92EE;'>#专访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20731, encryptionId=dba720e31b7, topicName=专访)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=070a30497323, createdName=flyingeagle87, createdTime=Mon Sep 05 15:33:00 CST 2016, time=2016-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48465, encodeId=3a1f48465eb, content=好文章,值得看。, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 17:17:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377590, encodeId=1d1f13e7590ce, content=<a href='/topic/show?id=5dfe4420fc' target=_blank style='color:#2F92EE;'>#CDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4420, encryptionId=5dfe4420fc, topicName=CDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec25412, createdName=yangpeizhi, createdTime=Tue Dec 15 02:33:00 CST 2015, time=2015-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540173, encodeId=891915401e39b, content=<a href='/topic/show?id=da548984604' target=_blank style='color:#2F92EE;'>#血糖监测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89846, encryptionId=da548984604, topicName=血糖监测)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50fd13191418, createdName=jktdtl, createdTime=Tue Dec 15 02:33:00 CST 2015, time=2015-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606768, encodeId=12321606e6869, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Dec 15 02:33:00 CST 2015, time=2015-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=46065, encodeId=8c9946065b4, content=指南熟记心中, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2d331664955, createdName=老段, createdTime=Mon Dec 14 07:32:00 CST 2015, time=2015-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=45774, encodeId=b1df45e740e, content=…………, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=554a1670659, createdName=yuwenpsy, createdTime=Sun Dec 13 22:26:00 CST 2015, time=2015-12-13, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1835606, encodeId=c48e18356060a, content=<a href='/topic/show?id=cfdc22e893f' target=_blank style='color:#2F92EE;'>#临床应用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22789, encryptionId=cfdc22e893f, topicName=临床应用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Mon Jul 18 15:33:00 CST 2016, time=2016-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703203, encodeId=dffd1e032037e, content=<a href='/topic/show?id=dba720e31b7' target=_blank style='color:#2F92EE;'>#专访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20731, encryptionId=dba720e31b7, topicName=专访)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=070a30497323, createdName=flyingeagle87, createdTime=Mon Sep 05 15:33:00 CST 2016, time=2016-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48465, encodeId=3a1f48465eb, content=好文章,值得看。, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 17:17:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377590, encodeId=1d1f13e7590ce, content=<a href='/topic/show?id=5dfe4420fc' target=_blank style='color:#2F92EE;'>#CDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4420, encryptionId=5dfe4420fc, topicName=CDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec25412, createdName=yangpeizhi, createdTime=Tue Dec 15 02:33:00 CST 2015, time=2015-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540173, encodeId=891915401e39b, content=<a href='/topic/show?id=da548984604' target=_blank style='color:#2F92EE;'>#血糖监测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89846, encryptionId=da548984604, topicName=血糖监测)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50fd13191418, createdName=jktdtl, createdTime=Tue Dec 15 02:33:00 CST 2015, time=2015-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606768, encodeId=12321606e6869, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Dec 15 02:33:00 CST 2015, time=2015-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=46065, encodeId=8c9946065b4, content=指南熟记心中, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2d331664955, createdName=老段, createdTime=Mon Dec 14 07:32:00 CST 2015, time=2015-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=45774, encodeId=b1df45e740e, content=…………, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=554a1670659, createdName=yuwenpsy, createdTime=Sun Dec 13 22:26:00 CST 2015, time=2015-12-13, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1835606, encodeId=c48e18356060a, content=<a href='/topic/show?id=cfdc22e893f' target=_blank style='color:#2F92EE;'>#临床应用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22789, encryptionId=cfdc22e893f, topicName=临床应用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Mon Jul 18 15:33:00 CST 2016, time=2016-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703203, encodeId=dffd1e032037e, content=<a href='/topic/show?id=dba720e31b7' target=_blank style='color:#2F92EE;'>#专访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20731, encryptionId=dba720e31b7, topicName=专访)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=070a30497323, createdName=flyingeagle87, createdTime=Mon Sep 05 15:33:00 CST 2016, time=2016-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48465, encodeId=3a1f48465eb, content=好文章,值得看。, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 17:17:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377590, encodeId=1d1f13e7590ce, content=<a href='/topic/show?id=5dfe4420fc' target=_blank style='color:#2F92EE;'>#CDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4420, encryptionId=5dfe4420fc, topicName=CDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec25412, createdName=yangpeizhi, createdTime=Tue Dec 15 02:33:00 CST 2015, time=2015-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540173, encodeId=891915401e39b, content=<a href='/topic/show?id=da548984604' target=_blank style='color:#2F92EE;'>#血糖监测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89846, encryptionId=da548984604, topicName=血糖监测)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50fd13191418, createdName=jktdtl, createdTime=Tue Dec 15 02:33:00 CST 2015, time=2015-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606768, encodeId=12321606e6869, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Dec 15 02:33:00 CST 2015, time=2015-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=46065, encodeId=8c9946065b4, content=指南熟记心中, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2d331664955, createdName=老段, createdTime=Mon Dec 14 07:32:00 CST 2015, time=2015-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=45774, encodeId=b1df45e740e, content=…………, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=554a1670659, createdName=yuwenpsy, createdTime=Sun Dec 13 22:26:00 CST 2015, time=2015-12-13, status=1, ipAttribution=)]
    2015-12-14 老段

    指南熟记心中

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1835606, encodeId=c48e18356060a, content=<a href='/topic/show?id=cfdc22e893f' target=_blank style='color:#2F92EE;'>#临床应用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22789, encryptionId=cfdc22e893f, topicName=临床应用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Mon Jul 18 15:33:00 CST 2016, time=2016-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703203, encodeId=dffd1e032037e, content=<a href='/topic/show?id=dba720e31b7' target=_blank style='color:#2F92EE;'>#专访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20731, encryptionId=dba720e31b7, topicName=专访)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=070a30497323, createdName=flyingeagle87, createdTime=Mon Sep 05 15:33:00 CST 2016, time=2016-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48465, encodeId=3a1f48465eb, content=好文章,值得看。, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 17:17:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377590, encodeId=1d1f13e7590ce, content=<a href='/topic/show?id=5dfe4420fc' target=_blank style='color:#2F92EE;'>#CDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4420, encryptionId=5dfe4420fc, topicName=CDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec25412, createdName=yangpeizhi, createdTime=Tue Dec 15 02:33:00 CST 2015, time=2015-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540173, encodeId=891915401e39b, content=<a href='/topic/show?id=da548984604' target=_blank style='color:#2F92EE;'>#血糖监测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89846, encryptionId=da548984604, topicName=血糖监测)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50fd13191418, createdName=jktdtl, createdTime=Tue Dec 15 02:33:00 CST 2015, time=2015-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606768, encodeId=12321606e6869, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Dec 15 02:33:00 CST 2015, time=2015-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=46065, encodeId=8c9946065b4, content=指南熟记心中, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2d331664955, createdName=老段, createdTime=Mon Dec 14 07:32:00 CST 2015, time=2015-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=45774, encodeId=b1df45e740e, content=…………, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=554a1670659, createdName=yuwenpsy, createdTime=Sun Dec 13 22:26:00 CST 2015, time=2015-12-13, status=1, ipAttribution=)]
    2015-12-13 yuwenpsy

    …………

    0

相关资讯

MedSci参加中华医学会糖尿病学分会第十九次全国学术会议(CDS 2015)

2015年12月9-12日,由中华医学会、中华医学会糖尿病学分会(CDS)主办的“中华医学会糖尿病学分会第十九次全国学术会议(CDS 2015)”在苏州举行。本次会议主题为“创新、规范、普及”,突出基础与临床结合、广度与深度并重、交流与培训并举、学术与公益兼顾等特点。本次会议恰逢中华医学会百年诞辰,会议规模、投稿数量、参会人数均创历史新高,共安排特邀学术报告268个,其中全体大会报告10个,专题研

CDS 2013:纪立农解读2013年版中国2型糖尿病防治指南

  在2013中华医学会糖尿病学分会第十七次全国学术会议上,中华医学会糖尿病学分会前任主任委员纪立农教授对即将修订并发布的2013年版《中国2型糖尿病防治指南》进行解读,同时,他希望学会内的成员能够脚踏实地地落实指南。   高血糖药物治疗以运动和营养治疗为基础  关于高血糖的药物治疗,纪立农教授指出,医学营养治疗和运动治疗是控制2型糖尿病高血糖的基本措施,2型糖尿病是一种进展性的疾病,随着病程的进

J Intern Med:艾塞那肽、胰岛素和吡格列酮对新诊断为2型糖尿病的影响(CONFIDENCE研究)

   据中山大学附属第三医院的许雯博士介绍,CONFIDENCE研究比较了3种具有β细胞保护作用的降糖药物——艾塞那肽、胰岛素和吡格列酮对新诊断为2型糖尿病患者的血糖控制和β细胞功能的影响。文章于8月5日在线发表于《内科学杂志》(J Intern Med)。 该多中心、随机、平行组试验共纳入416例新诊断的2型糖尿病患者,随机分入艾塞那肽、胰岛素、吡格列酮组

CDS 2015:洪天配解读DPP-4抑制剂与SGLT-2抑制剂在糖尿病治疗中的协同作用

北京大学第三医院内分泌科 洪天配教授 二肽基肽酶4(DPP-4)抑制剂与钠-葡萄糖协同转运蛋白-2(SGLT-2)抑制剂是两类新型降糖药物。研究显示,DPP-4酶抑制剂可通过直接作用于肾脏而发挥潜在的肾脏保护作用,而SGLT-2抑制剂则可通过改善肾小球高滤过状态而发挥肾脏保护作用。 本讲座主要从DPP-4酶抑制剂和SGLT-2抑制剂的作用机制、在肾损伤患者中的药代动力学、基础和临床研究相关

项坤三院士获首届CDS科学贡献奖

翁建平教授、纪立农教授、杨文英教授共同启动科学贡献奖 贾伟平教授介绍项坤三院士主要科学成果 多年来,中华医学会糖尿病学分会(CDS)一直致力于通过各种方式促进中国的糖尿病预防、基础和临床研究工作的开展。 CDS第七届委员会成立之后,决定自2014年起设立CDS科学贡献奖。科学贡献奖是CDS的最高学术奖项,旨在对国内的优秀科研成果和科研工作者进行奖励、表彰,并在

CDS 2013:杨文英认为DPP-4抑制剂是“智能化”降糖药

  肠促胰素机制研制的DPP-4抑制剂之所以目前被大家看好,很重要的原因是由于这类药物的作用机制完全不同于目前市面上其他的降糖药物。它在人体内的作用机制是多方面的:在胰岛方面,它可以在刺激β细胞分泌胰岛素的同时抑制胰高糖素的分泌,而且这种作用机制是具有葡萄糖浓度依赖性的,因而可以最大限度地防止低血糖的发生;另外,它还可以抑制食欲中枢,可以在很好控制血糖的同时不增加体重。在11月22日的2013

Baidu
map
Baidu
map
Baidu
map